SCHEMBL3560753

SCHEMBL3560753

O=C1NC(=O)c2ccc(Br)cc2C1=CNc1ccc(-c2cccnc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 2/20 0.46
TGM2 P21980 2/20 0.45
RAF1 P04049 2/20 0.42
PIK3C3 Q8NEB9 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
JAK3 P52333 2/20 0.40
JAK2 O60674 1/20 0.40
KDR P35968 2/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
PDPK1 O15530 1/20 0.38
AKT2 P31751 1/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
ABL1 P00519 1/20 0.38
RET P07949 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560750 1.00 TDP2 (0.46) TDP2TGM2RAF1PIK3C3CYP11B1
SCHEMBL3564133 0.88 MAOA (0.40) TDP2TGM2SMN1; SMN2
SCHEMBL3564130 0.88 MAOA (0.40) TDP2TGM2SMN1; SMN2
SCHEMBL13343914 0.77 DYRK1A (0.49) TDP2JAK3JAK2ABL1
SCHEMBL3573418 0.77 NPC1 (0.46) TGM2MAPTNPC1RAB9AMEN1
SCHEMBL3558054 0.77 MAOB (0.34) TDP2TGM2
SCHEMBL3567385 0.77 MAOB (0.41) CYP11B1LMNA
SCHEMBL3567380 0.77 MAOB (0.41) CYP11B1LMNA
SCHEMBL3558056 0.77 MAOB (0.34) TDP2TGM2
SCHEMBL3573416 0.77 NPC1 (0.46) TGM2MAPTNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 TDP2 511/4885TGM2 1223/4885RAF1 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.